CT 071
Alternative Names: CT-071; GPRC5D targeted CAR T cell therapy - CARsgen TherapeuticsLatest Information Update: 18 Jun 2024
At a glance
- Originator CARsgen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Leukaemia; Multiple myeloma
Most Recent Events
- 15 Jun 2024 Pharmacokinetics, efficacy and adverse events data from a phase 0 trial in Multiple myeloma and Leukemia presented the 29th Annual Congress of the European Hematology Association (EHA-2024)
- 06 Jun 2024 Phase-0 for Multiple myeloma (Newly diagnosed) in China (Parenteral) (NCT06407947)
- 09 May 2024 CARsgen Therapeutics plans a phase 0 trial for Multiple myeloma (Newly diagnosed) (Parenteral, Infusion) in May 2024 (NCT06407947)